Protara Therapeutics, Inc.
NASDAQ:TARABiotechnology
Healthcare
$2.34 -1.27%
-$0.05 today
- Market cap
- $144.07M
- Beta
- 1.45
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$1.48
52W Low $2.77High $7.82
Volume 1.15M
Average 0.73M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$64.55M
FY 2025 · Annual
Net Income
-$57.44M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 341K | 0 | 362K |
| Gross Profit | 0 | 0 | (341K) | 0 | (362K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 21.09M | 16.81M | 24.79M | 31.7M | 42.63M |
| Selling, General & Admin | 26.4M | 20.74M | 18.62M | 17.45M | 21.92M |
| Operating Expenses | 47.49M | 67.06M | 43.27M | 49.15M | 64.19M |
| Depreciation & Amortization | 117K | 248K | 341K | 332K | 362K |
| EBITDA | (45.4M) | (64.57M) | (40.08M) | (44.26M) | (57.08M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (47.49M) | (67.06M) | (43.61M) | (49.15M) | (64.55M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 237K | 1.11M | 2.73M | 4.14M | 6.33M |
| Interest Expense | 1.74M | 1.14M | 0 | 0 | 0 |
| Other Income / Expenses | 237K | 1.11M | 3.19M | 4.56M | 7.11M |
| Income Before Tax | (47.25M) | (65.95M) | (40.42M) | (44.6M) | (57.44M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (47.25M) | (65.95M) | (40.42M) | (44.6M) | (57.44M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (4.20) | (5.86) | (3.57) | (2.17) | (1.34) |
| EPS (Diluted) | (4.20) | (5.86) | (3.57) | (2.17) | (1.34) |
| 11.23M | 11.26M | 11.33M | 20.59M | 42.84M | |
| 11.23M | 11.26M | 11.33M | 20.59M | 42.84M |
TARA Earnings Waterfall · TTM
NASDAQ:TARA · Revenue to Net Income
Key Ratios
EPS$-1.46
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-3.1
P/S Ratio0.0
Analysis
$0 of revenue converted into -$63.3M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.46, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 6, 2026 | |
| 10-Q | Quarterly report | Nov 6, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 13, 2026 | |
| 8-K | Current report | Aug 11, 2026 | |
| S-8 | S-8 filing | Aug 11, 2026 |
How much revenue does TARA generate?
Protara Therapeutics, Inc. (TARA) reported $0.00 of revenue in fiscal 2025.
Is TARA profitable?
Protara Therapeutics, Inc. (TARA) reported -$57.44M of net income.
Continue the stock analysis
Jump to another research area for this company.